Janus Henderson Group PLC grew its holdings in Insulet Co. (NASDAQ:PODD – Free Report) by 14.6% during the third quarter, ...

Right now, ResMed is sporting a Zacks Rank of #2 (Buy), while Insulet has a Zacks Rank of #3 (Hold). This means that RMD's earnings estimate revision activity has been more impressive, so investors ...

Insulet Corp., manufacturer of the tubeless Omnipod Insulin Management System, has been awarded $452 million in damages after it successfully defended its intellectual property against ...

With 27 witnesses, plus both patent infringement and misappropriation claims, lead counsel for Insulet Alexandra Valenti and ...

In a report released yesterday, Robbie Marcus from J.P. Morgan maintained a Buy rating on Insulet (PODD – Research Report), with a price target ...